Posts by: Daniela Semedo, PhD

Daniela Semedo, PhD

Daniela holds a PhD in Clinical Psychology from The University of Edinburgh, United Kingdom, a MSc in Health Psychology and a BSc in Clinical Psychology. Her work has been focused on vulnerability to psychopathology and early identification and intervention in psychosis.

May 19, 2016May 19, 2016

Veracyte Shows New Drug Data for IPF Diagnosis at ATS 2016

Idiopathic Pulmonary Fibrosis, News

Veracyte presented data at the recent American Thoracic Society (ATS) 2016 International Conference from a study proving the potential of its Envisia classifier to improve the diagnosis of interstitial lung diseases, ... Read more

May 18, 2016May 18, 2016

Positive Interim Data for Pulmonary Hypertension Phase 2a Study Presented by Mast Therapeutics

News, Pulmonary Hypertension

Mast Therapeutics presented positive interim data from its Phase 2a clinical trial of the investigational drug AIR001 in patients with pulmonary hypertension (PH) associated with heart failure with preserved ejection fraction ... Read more

May 17, 2016May 25, 2016

Actelion’s Uptravi for PAH Granted Marketing Authorization by European Commission

News, Pulmonary Hypertension

The European Commission recently granted marketing authorization in the EU for Switzerland-based Actelion’s product Uptravi (selexipag) for the treatment of pulmonary arterial hypertension. PAH is a life-threatening disease characterized by abnormal constriction of the pulmonary ... Read more

May 12, 2016May 13, 2016

Veracyte to Show Data on Lung Disease Genomic Classifiers at ATS 2016

Idiopathic Pulmonary Fibrosis, Lung Cancer, News

Veracyte, Inc. will present results at the American Thoracic Society (ATS) 2016 International Conference from multiple trials supporting the company’s genomic tests that may resolve uncertainty in lung disease diagnosis. The company ... Read more

May 11, 2016May 11, 2016

Study Bolsters Support for Newborn Cystic Fibrosis Screenings in Quebec

Cystic Fibrosis, News

A new study led by a team from the Research Institute of the McGill University Health Centre (RI-MUHC) and Cystic Fibrosis Canada strongly supports the benefits of newborn screening programs ... Read more

May 9, 2016May 9, 2016

Insmed Incorporated to Present Data on Liposomal Technology To Treat PAH, IPF at 2016 American Thoracic Society Meeting

Asthma, News, Pulmonary Hypertension

Insmed Incorporated recently announced that it will present three ARIKAYCE™-related abstracts and one treprostinil prodrug abstract at the American Thoracic Society (ATS) 2016 International Conference in San Francisco, May 13-18. ARIKAYCE™ ... Read more

May 5, 2016May 5, 2016

AVEO Oncology Files Provisional Patent Applications for AV-353 for PAH Treatment

News, Pulmonary Hypertension

AVEO Oncology recently filed provisional patent applications with the United States Patent and Trademark Office (USPTO) covering composition of matter claims for AV-353, its Notch 3 inhibitory antibody. These are the ... Read more

May 2, 2016May 2, 2016

Cumberland Pharmaceuticals to Begin Development of Scleroderma Drug Vasculan

News, Scleroderma

Cumberland Pharmaceuticals recently added Vasculan to its clinical portfolio. The company has began the clinical development of Vasculan (ifetroban) oral capsule for the treatment of systemic sclerosis (SSc), also know ... Read more

April 28, 2016May 31, 2016

Scientists Discover Shared Genes in COPD and IPF, Pointing to Potential Drug Development

COPD, Emphysema, Idiopathic Pulmonary Fibrosis, News

Despite sharing some risk factors, chronic obstructive pulmonary disease (COPD) and idiopathic pulmonary fibrosis (IPF) are usually studied in isolation, and the presence of possible shared molecular mechanisms has been unknown. Now, in a new study ... Read more

April 27, 2016April 27, 2016

Physical Therapy Program Improves COPD Patients’ Quality of Life, Researchers Say

COPD, News

Researchers at the University of Granada (UGR) and Virgen de las Nieves Hospital, Spain, developed a brief physical therapy treatment of 7 to 10 days that demonstrates it can improve ... Read more